To evaluate the efficacy and the rate of side effects of the pegylated aptamer pegaptanib in the treatment of patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) and a history of previous arterial thromboembolic events (ATEs).
Twenty-three eyes of 23 patients with subfoveal CNV due to AMD and cerebrovascular accidents (n = 12) and myocardial infarction (n = 11) in the previous 6 months received intravitreal pegaptanib 0.3 mg according to a pro re nata regimen and were followed for 12 months. The paired Student t test was used to evaluate mean changes in best-corrected visual acuity (BCVA; primary outcome measure) and central foveal thickness (CFT).
The mean patient age was 71.5 ± 4.6 years; there were 14 women and 9 men. The CNV was type 1, 2, and 3 in 18, 3, and 2 eyes, respectively. The mean BCVA improved from 0.67 ± 0.23 logMAR at baseline to 0.52 ± 0.31 logMAR at the end of 12-month follow-up (p = 0.044). Thirty-five percent of patients achieved ≥3 Early Treatment Diabetic Retinopathy Study lines improvement at 12 months. Mean CFT at baseline (381 ± 111 µm) decreased to 304 ± 82 µm at 12 months (p = 0.008). Patients received a mean of 4.3 ± 1.3 (range 3-7) injections. No systemic or ocular side effects occurred; no patient experienced further ATEs.
Intravitreal pegaptanib can be considered a viable treatment option for patients with AMD-related CNV who are at high risk of ATEs.
Post author correction
Article Type: ORIGINAL RESEARCH ARTICLE
Article Subject: Retina MED
AuthorsMaurizio Battaglia Parodi, Emanuele Di Bartolo, Claudia Brue, Ezio Cappello, Claudio Furino, Sebastiano Giuffrida, Manuela Imparato, Michele Reibaldi
- • Accepted on 04/10/2017
- • Available online on 25/10/2017
This article is available as full text PDF.
- Battaglia Parodi, Maurizio [PubMed] [Google Scholar] 1, * Corresponding Author (email@example.com)
- Di Bartolo, Emanuele [PubMed] [Google Scholar] 2
- Brue, Claudia [PubMed] [Google Scholar] 3
- Cappello, Ezio [PubMed] [Google Scholar] 4
- Furino, Claudio [PubMed] [Google Scholar] 5
- Giuffrida, Sebastiano [PubMed] [Google Scholar] 6
- Imparato, Manuela [PubMed] [Google Scholar] 7
- Reibaldi, Michele [PubMed] [Google Scholar] 8
Department of Ophthalmology, Ospedale San Raffaele, Milan - Italy
Department of Ophthalmology, Azienda Ospedaliero-Universitaria Pisana, Pisa - Italy
Department of Ophthalmology, Polytechnic University of Marche, Ancona - Italy
Department of Ophthalmology, Ospedale San Bassiano, Bassano del Grappa - Italy
Department of Ophthalmology, University of Bari, Bari - Italy
Bausch and Lomb Iom SpA, Vimodrone, Milan - Italy
Department of Ophthalmology, Fondazione IRCCS Policlinico San Matteo, Pavia - Italy
Department of Ophthalmology, University of Catania, Catania - Italy